MTOR and cancer: However, levels of key intermediates of cancer pro-survival pathways (p-mTOR, p-AKT, and p-ERK) were neither diminished when apoptosis was increased (e.g., in CD151-KO cells), nor elevated when apoptosis was reduced (e.g., in CD151 reconstituted cells).